Conclusion
Findings support the sustained efficacy and long-term safety of ravulizumab, administered every 8 weeks, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.ClinicalTrials.gov identifier: NCT03920293; EudraCT: 2018-003243-39.